SUSMED, Inc. is a Japanese digital therapeutics (DTx) company focused on developing software-based medical treatments, including a regulatory-approved therapeutic app for insomnia disorder (approved by Japan's MHLW in February 2023, with a partial change approval in September 2025). The company operates two segments: the DTx Product Business, which develops and commercializes therapeutic apps across disease areas, and the DTx Platform Business, which provides a proprietary clinical trial management system and machine learning-based automated medical data analysis tools to pharmaceutical companies, academic institutions, CROs, and medical institutions. SUSMED's competitive strengths lie in its integrated ICT-driven approach to reducing clinical development costs and timelines, while enabling remote clinical trials and real-world data utilization.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →SUSMED, Inc. is a Japanese digital therapeutics (DTx) company focused on developing software-based medical treatments, including a regulatory-approved therapeutic app for insomnia disorder (approved by Japan's MHLW in February 2023, with a partial change approval in September 2025). The company operates two segments: the DTx Product Business, which develops and commercializes therapeutic apps across disease areas, and the DTx Platform Business, which provides a proprietary clinical trial management system and machine learning-based automated medical data analysis tools to pharmaceutical companies, academic institutions, CROs, and medical institutions. SUSMED's competitive strengths lie in its integrated ICT-driven approach to reducing clinical development costs and timelines, while enabling remote clinical trials and real-world data utilization.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →